Skip to main content

Drug-Induced Nephrotoxicity!

 DRUG-INDUCED NEPHROTOXICITY

  • Drug-Induced Nephrotoxicity is increasingly recognized as a significant contributor to kidney disease including Acute Kidney Injury (KI) and chronic kidney disease (CKD).
  • Nephrotoxicity has a wide spectrum, reflecting damage to different nephron segments based upon individual drug-mechanisms.


1. ACE-INHIBITORS:

  • ACE-Inhibitors are frequently associated with Proteinuria and Renal Insufficiency.
  • The prevalence of Proteinuria in Captopril treated patient is estimated to be 1%.
  • The risk of Renal Insufficiency is greater with long-acting ACE Inhibitors such as Lisinopril or Enalapril than with Captopril.
  • Immune complex glomerulopathy is a major contribute to ACE Inhibitor nephrotoxicity.
  • Predisposing factors include:

  1. Hyponatremia
  2. Diuretic therapy
  3. Pre-existing renal impairment
  4. Congestive Heart Failure (CHF)
  5. Diabetes Mellitus

  • Recovery of renal function usually follows ACE-Inhibitor discontinuation.


2. CEPHLOSPORIN:

  • The cephalosporin antibiotics are capable of producing rare Interstitial Nephritis similar to Penicillin's.
  • Increase in BUN and Cr(s) occur occasionally.
  • Nephrotoxicity of newer drugs is minimal compared with older such as Cephalothin.


3. DIURETICS(THIAZIDE):

  • Occasional cases of Interstitial Nephritis have been reported, which might be the result of hypersensitivity reaction.
  • Lomg-term use of diuretics increases the risk of Renal cell carcinoma, especially in women.


4. NSAIDs:

  • NSAIDs including COX-2 Inhibitors can reduce Cr (Cl) and produce renal insufficiency as a result of renal circulatory changes caused by inhibition of PG synthesis. These effects are usually reversible.
  • The prevalence is usually 1%.
  • Predisposing factors include:

  1. Old age
  2. Preexisting renal impairment
  3. Hypotension
  4. CHF
  5. Hepatic cirrhosis

  • Fenoprofen is the NSAID most commonly associated with interstitial nephritis and nephrotic syndrome.


5. OMEPRAZOLE:

  • Interstitial nephritis occurs rarely during omeprazole therapy.
  • At least 13 cases were published; 10 with positive biopsies; 5 cases were rechallenged with recurrence of interstitial nephritis in all.
  • Onset is usually after 2 weeks to 6 months of Omeprazole therapy.


Labels:

Comments

Post a Comment

Popular posts from this blog

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD)
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-50mg/dL and A1c level
Post a Comment
Read more

GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)!

MANAGEMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE  "GERD refers to the endoscopically determined esophagitis or endoscopy-negative reflux disease" . "GERD is the term used to describe any symptomatic clinical condition or histopathological alteration resulting from episodes of reflux of acid, pepsin and occasionally, bile into the esophagus from the stomach". Patients with uninvestigated "reflux-like" symptoms should be managed as patients with uninvestigated dyspepsia. There is currently no evidence that H.pylori should be investigated in patients with GERD. Symptoms: Heartburn is the characteristic symptom of GERD. Acid regurgitation Dysphagia Belching Upper abdominal discomfort Bloating and postprandial fullness Chest pain Hoarseness Cough Complications include: Esophageal ulceration Formation of specialized columnar-lined esophagus at the gastro-esophageal junction known as Barretts Esophagus . Mechanism of Acid Reflux: The mechanism of acid reflux is mu
Post a Comment
Read more